FDA’s ‘key man’ Peter Marks is out. Biotech investors will now deal with the consequences For investors, Marks’ ouster is a worst-case scenario realized — an FDA riven by dysfunction and uncertainty

https://www.statnews.com/2025/03/30/fda-key-man-peter-marks-out-biotech-investors-deal-with-consequences/